Diabetic Eye Disease

Amid conflicting findings, factors such as dosage, patient characteristics may affect outcomes.

Conditionally accepted by the FDA as EYO-1901, DURAVYU is a tyrosine kinase inhibitor intended to improve signs and symptoms of non-proliferative diabetic retinopathy in the PAVIA trial.

Older age and longer duration of type 1 diabetes also play a role in the development of diabetic retinopathy, according to a chart review.

The diagnostic screening technology is able to diagnose diabetic retinopathy by using 1 image taken of each eye with over 99% imageability.

The company stated that 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, FAAO, recap the diverse topics at EyeCon 2023, emphasizing the collaborative spirit between optometrists and ophthalmologists in addressing issues such as myopia management, diabetic eye conditions, cataract surgery, and patient referrals.

Community-based eye care is one of Orbis’s top priorities in the country.

Is telemedicine through retinal images a solution to earlier intervention and increased access to care? Fortunately—and unfortunately—yes.

Counsel your at-risk patients on strategies to minimize severe hypoglycemia.

T1D is one of the most common chronic diseases affecting pediatric populations.

A new study titled, “Prevalence of Diabetic Retinopathy in the US in 2021,” finds that almost 10 million people in the United States with diabetes have diabetic retinopathy.

As part of the American Diabetes Association's Health Equity Now program, the organization has partnered with Genentech, piloting a partnership within Alabama to specifically focusing on tackling barriers related to diabetic eye disease.

According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.

The DR:EAM study in investigating novel eye drop OTT-166 for the treatment of diabetic retinopathy in hopes of reducing treatment burden for patients.

A look back on what happened in optometry during the week of March 20-March 24.

These disorders account for most of the vision loss in working-age and elderly Americans.

Paul Chous, MA, OD, FAAO, gives key takeaways from his 2023 SECO presentation on diabetes: then and now.

The Biologics License Application for aflibercept 8 mg was supported by positive data from the PULSAR study, investigating wet AMD, and the PHOTON study, investigating DME.

These results emphasize the importance of evaluating the midperipheral and peripheral retina in diabetes in addition to the posterior pole and performing ultra-widefield fluorescein angiography for not only accurate diabetic retinopathy staging, but also for likelihood of significant progression based on disease severity and predominantly peripheral lesions.

As Baby Boomers enter the at-risk age group for vision loss, optometrists must be ready to act.

Case history can give clues to a patient’s risk of developing diabetic eye disease.

Teplizumab may work by binding to certain immune system cells that attack insulin-producing cells and increase the proportion of cells that help moderate the immune response, thus delaying progression to stage 3 type 1 diabetes.

Sherrol A. Reynolds, OD, FAAO, shares highlights from her discussion, "The OD's role in addressing silent killers: diabetes, hypertension, and dyslipidemia," which she presented during this year's American Academy of Optometry annual meeting.

New DME treatments aim to extend time between intravitreal injections.

A recent clinical trial from the DRCR Retina Network examined a stepped regimen of anti-VEGF drugs bevacizumab and aflibercept.

Proper screenings, treatment, management needed for this increasingly prevalent disease.

The patient’s ocular history was significant for severe nonproliferative diabetic retinopathy (NPDR) in the right eye (OD) and mild NPDR in the left eye (OS), which had been diagnosed 4 years previously at his last eye exam.

The ADA now recommends an individualized approach at diagnosis of diabetes as well as for adults who do not have symptoms to be screened at age 35 years.

Addressing common misconceptions can help avoid misconstrued scientific facts

Timing is key in reducing the risk of developing vision loss or blindness.